Nanjing Vazyme Biotech Revenue

In the year 2025, Nanjing Vazyme Biotech had annual revenue of 1.38B CNY, down -0.00%. Nanjing Vazyme Biotech had revenue of 425.48M in the quarter ending December 31, 2025, with 8.54% growth.

Revenue

1.38B

Revenue Growth

-0.00%

P/S Ratio

5.78

Revenue / Employee

480.60K

Employees

2,754

Market Cap

7.96B

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.38B	-16.98K	-0.00%
Dec 31, 2024	1.38B	91.91M	7.15%
Dec 31, 2023	1.29B	-2.28B	-63.97%
Dec 31, 2022	3.57B	1.70B	90.99%
Dec 31, 2021	1.87B	304.17M	19.44%
Dec 31, 2020	Pro	Pro	Pro
Dec 31, 2019	Pro	Pro	Pro
Dec 31, 2018	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Chengdu Kanghua Biological Products	1.21B
Anhui Huaheng Biotechnology	2.89B
Suzhou Fengbei Biotech Stock	2.81B
Jiangxi Fushine Pharmaceutical	970.32M
Zhejiang Ausun Pharmaceutical	751.12M
Youcare Pharmaceutical Group	2.45B
Acrobiosystems	794.52M
Daan Gene	765.48M

Revenue Rankings